Clinical Trials
15 trialsNCT00814021 2026-04-15
Sunitinib in Treating Patients With Kidney Cancer That Has Spread to the Brain
Institut Claudius Regaud
Phase 2 Completed
NCT00843037 2024-10-17
SNIPP
University Health Network, Toronto
Phase 2 Completed
NCT00270413 2022-11-22
SU11248 as Consolidation After Response to Taxanes in Metastatic Breast Cancer
Universitaire Ziekenhuizen KU Leuven
Phase 2 Completed
NCT02432846 2022-08-22
MERECA
Mendus
Phase 2 Completed
NCT01694277 2020-12-08
Masitinib in Patients With Gastrointestinal Stromal Tumour After Progression With Imatinib
AB Science
Phase 3 Completed
NCT01551459 2019-10-29
SUAVE
The Clatterbridge Cancer Centre NHS Foundation Trust
Phase 2 Completed
NCT01309633 2019-07-22
Study Evaluating Two Loading Regimens of Sunitinib or Bevacizumab Alternating With Cisplatin and Gemcitabine as Induction Therapy for Locally Advanced Nasopharyngeal Carcinoma (NPC)
National University Hospital, Singapore
Phase 2 Completed
NCT02142036 2019-03-13
MetAction
Oslo University Hospital
Phase 2 Completed
NCT02623127 2019-01-23
KOSMIC
Seoul National University Hospital
Phase 2 Completed
NCT00556049 2016-04-21
Combination Sunitinib and Gemcitabine in Sarcomatoid and/or Poor-risk Patients With Metastatic Renal Cell Carcinoma
Massachusetts General Hospital
Phase 2 Completed
NCT00462982 2015-12-30
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00886132 2015-07-23
A Study of Sunitinib in Recurrent and/or Metastatic Adenoid Cystic Carcinoma of the Salivary Glands
University Health Network, Toronto
Phase 2 Completed
NCT00299741 2012-12-19
Study of SU11248 in Men With Advanced Prostate Cancer
Massachusetts General Hospital
Phase 2 Completed
NCT00434109 2012-09-14
Phase II Study of Sunitinib Malate Following Hepatic Artery Embolization
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00421512 2008-11-11
A Phase I Study of Bevacizumab and Sunitinib in Metastatic Renal Cell Carcinoma Patients
Memorial Sloan Kettering Cancer Center
Phase 1 Completed